Puri Mail

(Albany, US) On November 02, 2026, DelveInsight’s “Cardiac Insufficiency Pipeline Insights 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Cardiac Insufficiency pipeline landscape. It covers the Cardiac Insufficiency pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cardiac Insufficiency pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Cardiac Insufficiency Pipeline @ https://www.delveinsight.com/sample-request/cardiac-insufficiency-pipeline-insight

Key Takeaways from the Cardiac Insufficiency Pipeline Report

• On October 22, 2026 – VisCardia announced the publication of results from its RECOVER-HF pilot trial in JACC: Heart Failure. The study evaluated the investigational VisONE Synchronized Diaphragmatic Stimulation Therapy in patients with symptomatic HFrEF. The findings will help inform the ongoing pivotal RECOVER-HF trial, which is assessing the therapy’s potential to improve outcomes in patients with heart failure.
• On October 21, 2026 – Noah Labs announced the initiation of its pivotal VOICE-HF study, enrolling the first patients to evaluate Noah Labs Vox, an investigational voice-based AI medical device designed to detect signs of worsening heart failure through daily voice recordings. The multicenter study is expected to enroll approximately 450 patients and generate evidence to support a potential FDA De Novo submission.
• On October 11, 2026 – Cardurion Pharmaceuticals presented Phase II results from its Cycle clinical program evaluating tovinontrine (CRD-750) in patients with heart failure. In the Cycle-1 trial, two of the three tested doses demonstrated reductions in NT-proBNP levels in patients with heart failure with reduced ejection fraction (HFrEF). The treatment also showed a favorable safety and tolerability profile.
• DelveInsight’s Cardiac Insufficiency pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Cardiac Insufficiency treatment.
• The leading Cardiac Insufficiency Companies include AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Pfizer, HELP Therapeutics Co., Ltd., Novo Nordisk A/S, Tasly Pharmaceutical Group Co., Ltd, Boehringer Ingelheim, Bristol-Myers Squibb, Sardocor Corp., Biopeutics Co., Ltd and others.
• Promising Cardiac Insufficiency Pipeline Therapies such as Baxdrostat, CDR132L, LY3971297 and others.

Stay ahead with the most recent Cardiac Insufficiency pipeline outlook with DelveInsight @ Cardiac Insufficiency Treatment Drugs

The Cardiac Insufficiency Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Cardiac Insufficiency Pipeline Report also highlights the unmet needs with respect to the Cardiac Insufficiency.

Cardiac Insufficiency Overview

Cardiac Insufficiency (Heart Failure) is a chronic clinical syndrome in which the heart is unable to pump sufficient blood to meet the body’s metabolic demands or can do so only at elevated filling pressures. It is not a condition where the heart stops working; rather, it reflects impaired cardiac function due to structural or functional abnormalities. Cardiac insufficiency may involve the left ventricle, right ventricle, or both, and is commonly classified as heart failure with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), or preserved ejection fraction (HFpEF). The condition is a leading cause of hospitalization and mortality worldwide, particularly among older adults.

Cardiac Insufficiency Emerging Drugs Profile

• Baxdrostat: AstraZeneca

Baxdrostat is an investigational, orally administered, highly selective aldosterone synthase (CYP11B2) inhibitor being developed by AstraZeneca for the treatment of uncontrolled and treatment-resistant hypertension, with potential applications in cardiovascular and renal diseases. By selectively inhibiting aldosterone production while sparing cortisol synthesis, baxdrostat aims to reduce blood pressure with fewer off-target endocrine effects. The therapy has demonstrated promising blood pressure-lowering efficacy in Phase II studies and is currently being evaluated in Phase III clinical trials.

• CDR132L: Novo Nordisk A/S

CDR132L is an investigational antisense oligonucleotide targeting microRNA-132 (miR-132), being developed by Novo Nordisk A/S for the treatment of heart failure. By inhibiting miR-132, CDR132L aims to reduce adverse cardiac remodeling, improve myocardial function, and slow progression of heart failure. The therapy has demonstrated encouraging safety and biomarker improvements in early clinical studies and is advancing through clinical development for patients with impaired cardiac function. The drug is in Phase II for the treatment of heart failure.

• LY3971297: Eli Lilly and Company

LY3971297 is an investigational, orally administered aldosterone synthase (CYP11B2) inhibitor being developed by Eli Lilly and Company for the treatment of hypertension and cardiorenal diseases associated with excess aldosterone production. The therapy is designed to selectively suppress aldosterone synthesis while preserving cortisol production, potentially offering improved safety compared with less selective agents. LY3971297 is currently in early-to-mid stage clinical development to evaluate its efficacy, safety, and blood pressure-lowering potential in patients with hypertension. As per the clinical trials the drug is in Phase I for heart failure.

The Cardiac Insufficiency Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Cardiac Insufficiency with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cardiac Insufficiency Treatment.
• Cardiac Insufficiency Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cardiac Insufficiency Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cardiac Insufficiency market

Explore groundbreaking therapies and clinical trials in the Cardiac Insufficiency Pipeline @ New Cardiac Insufficiency Drugs

Cardiac Insufficiency Companies

AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Pfizer, HELP Therapeutics Co., Ltd., Novo Nordisk A/S, Tasly Pharmaceutical Group Co., Ltd, Boehringer Ingelheim, Bristol-Myers Squibb, Sardocor Corp., Biopeutics Co., Ltd and others.

Cardiac Insufficiency Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Cardiac Insufficiency Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Cardiac Insufficiency Market Drivers and Barriers

Scope of the Cardiac Insufficiency Pipeline Report

• Coverage- Global
• Cardiac Insufficiency Companies- AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Pfizer, HELP Therapeutics Co., Ltd., Novo Nordisk A/S, Tasly Pharmaceutical Group Co., Ltd, Boehringer Ingelheim, Bristol-Myers Squibb, Sardocor Corp., Biopeutics Co., Ltd and others.
• Cardiac Insufficiency Pipeline Therapies- Baxdrostat, CDR132L, LY3971297 and others
• Cardiac Insufficiency Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cardiac Insufficiency Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Cardiac Insufficiency Therapies and clinical trials @ Cardiac Insufficiency Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Cardiac Insufficiency: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cardiac Insufficiency – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Cardiac Insufficiency Collaboration Deals
9. Late Stage Products (Pre-registration)
10. Baxdrostat: AstraZeneca
11. Late Stage Products (Phase III)
12. Mid Stage Products (Phase II)
13. CDR132L: Novo Nordisk A/S
14. Comparative Analysis
15. Early Stage Products (Phase I/II)
16. LY3971297: Eli Lilly and Company
17. Comparative Analysis
18. Cardiac Insufficiency Key Companies
19. Cardiac Insufficiency Key Products
20. Cardiac Insufficiency Unmet Needs
21. Cardiac Insufficiency Market Drivers and Barriers
22. Cardiac Insufficiency Future Perspectives and Conclusion
23. Cardiac Insufficiency Analyst Views
24. Cardiac Insufficiency Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/cardiac-insufficiency-pipeline-insight